Paxlovid^® (nirmatrelvir and ritonavir) PBS listing

Updated September 2022

Commencing 1 May 2022 Paxlovid^® (nirmatrelvir and ritonavir) will be listed on the Pharmaceutical Benefits Scheme as a General Schedule, Authority Required (STREAMLINED) benefit for patients with mild-moderate COVID 19 who have a high risk for developing severe disease, reducing the need for admission to hospital.

Additional information can be found in the Covid 19 Fact sheets.